YU43996A - Upotreba duloksetina za proizvodnju leka i njegova farmaceutska kompozicija - Google Patents

Upotreba duloksetina za proizvodnju leka i njegova farmaceutska kompozicija

Info

Publication number
YU43996A
YU43996A YU43996A YU43996A YU43996A YU 43996 A YU43996 A YU 43996A YU 43996 A YU43996 A YU 43996A YU 43996 A YU43996 A YU 43996A YU 43996 A YU43996 A YU 43996A
Authority
YU
Yugoslavia
Prior art keywords
duloxetine
application
pharmaceutical composition
medicament production
compound
Prior art date
Application number
YU43996A
Other languages
English (en)
Inventor
Harrison Heiligenstein John
Coleman Laguzza Bennett
Marc Paul Steven
Dennis Tollefson Gary
Original Assignee
Eli Lilly Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9525909.9A external-priority patent/GB9525909D0/en
Application filed by Eli Lilly Company filed Critical Eli Lilly Company
Publication of YU43996A publication Critical patent/YU43996A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Opisano je korišćenje jedinjenja formule (I) u kojoj X predstavlja C1-C4 alkiltio a Y jeC1-C2 alkil, ili njen stereoizomer ili farmaceutski prihvatljiva so, za proizvodnju leka za tretiranje poremećaja nedostatka pažnje/hiperaktivnosti, koji se sastoji od tog jedinjenja i farmaceutskog nosača. Jedinjenje koje za ovu svrhu koristi je N-metil-3-(2-metiltiofenoksi)-3-fenilpropilamin ili njegov stereoizomer ili njegova farmaceutski prihvatljiva so.
YU43996A 1995-07-24 1996-07-23 Upotreba duloksetina za proizvodnju leka i njegova farmaceutska kompozicija YU43996A (sh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US137395P 1995-07-24 1995-07-24
US634995P 1995-11-08 1995-11-08
GBGB9525909.9A GB9525909D0 (en) 1995-12-19 1995-12-19 Treatment of attention-defecit/hyperactivity disorder

Publications (1)

Publication Number Publication Date
YU43996A true YU43996A (sh) 1999-06-15

Family

ID=27268037

Family Applications (1)

Application Number Title Priority Date Filing Date
YU43996A YU43996A (sh) 1995-07-24 1996-07-23 Upotreba duloksetina za proizvodnju leka i njegova farmaceutska kompozicija

Country Status (14)

Country Link
EP (1) EP0756869A3 (sh)
JP (1) JPH11510143A (sh)
KR (1) KR19990035817A (sh)
CN (1) CN1195287A (sh)
AU (1) AU709704B2 (sh)
CA (1) CA2227410A1 (sh)
CZ (1) CZ16798A3 (sh)
EA (1) EA000856B1 (sh)
IL (1) IL122984A0 (sh)
MX (1) MX9800589A (sh)
NO (1) NO980251L (sh)
NZ (1) NZ313076A (sh)
WO (1) WO1997003665A1 (sh)
YU (1) YU43996A (sh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
EP1069900B1 (en) * 1998-04-09 2005-08-10 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of neuropsychiatric disorders
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US7384941B2 (en) 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
US20070032554A1 (en) * 2003-08-27 2007-02-08 Elililly And Company A Corporation Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
BR112015005894B1 (pt) 2012-09-18 2022-03-29 Auspex Pharmaceuticals, Inc Composto, composição farmacêutica, método para tratar um distúrbio mediado por vmat2 e formulação farmacêutica de liberação prolongada
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN114796209A (zh) 2015-03-06 2022-07-29 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
JP2020029447A (ja) * 2018-06-25 2020-02-27 大原薬品工業株式会社 腸溶性高分子及び抗付着剤を含有する顆粒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
ES2077358T3 (es) * 1992-10-08 1995-11-16 Lilly Co Eli N-alquil-3-fenil-3-(2-alquiltiofenoxi)propilaminas.
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
CN1195287A (zh) 1998-10-07
NO980251D0 (no) 1998-01-20
NO980251L (no) 1998-01-20
NZ313076A (en) 1999-11-29
EP0756869A3 (en) 1999-06-16
KR19990035817A (ko) 1999-05-25
AU6506196A (en) 1997-02-18
CA2227410A1 (en) 1997-02-06
JPH11510143A (ja) 1999-09-07
EA199800152A1 (ru) 1998-08-27
WO1997003665A1 (en) 1997-02-06
MX9800589A (es) 1998-04-30
EA000856B1 (ru) 2000-06-26
CZ16798A3 (cs) 1998-11-11
AU709704B2 (en) 1999-09-02
IL122984A0 (en) 1998-08-16
EP0756869A2 (en) 1997-02-05

Similar Documents

Publication Publication Date Title
YU43996A (sh) Upotreba duloksetina za proizvodnju leka i njegova farmaceutska kompozicija
SE9504661D0 (sv) New compounds
PT814796E (pt) Uso de um farmaco r-aine numa composicao protectora para o tratamento do cancro colorectal
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
MY132705A (en) Novel compounds with analgesic effect
DE502004011581D1 (de) Verwendung von rotigotin zur behandlung von depressionen
HRP20020088B1 (en) Levodopa/carbidopa/entacapone pharmaceutical preparation
YU191491A (sh) Nova so 3- 2-(dimetilamino)etil -n-metil-14-indol-5-metansulfonamida
ES2183841T3 (es) Formas de dosificacion para administrar un farmasco en una formulacion lquidid.
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
NZ502853A (en) Treatment of conduct disorder with a norepinephrine reuptake inhibitor such as tomoxetine
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
SE9900961D0 (sv) Novel compounds
SE9802208D0 (sv) Novel compounds
DE60035133D1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
AU2002223970A1 (en) Kyberdrug as autovaccines with immune-regulating effects
GEP20043231B (en) Resorcinol Composition
RS50523B (sr) Farmaceutska kompozicija koja sadrži cink-hijaluronat kompleks za lečenje multiple skleroze
SE9900190D0 (sv) New compounds
ATE245980T1 (de) Verwendung eines pyruvatdehydrogenaseaktivators zur behandlung der ischämie in gliedern
GEP20043301B (en) Heterocyclic Amide Derivatives, Pharmaceutical Compositions Containing the Same and Use Thereof for Treatment of Inflammation and Other Immune Disorders
SE9202218D0 (sv) Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation
NO975790L (no) Anvendelse av allylaminderivater slik som terbinafin, i fremstillingen av et medikament for behandling av helikobacterpylori-infeksjonsassosierte sykdommer